Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?

Malapelle U, Rossi A, Bria E.

J Thorac Dis. 2019 Sep;11(Suppl 15):S1837-S1840. doi: 10.21037/jtd.2019.08.99. No abstract available.

2.

Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.

Gobbini E, Chiari R, Pizzutillo P, Bordi P, Ghilardi L, Pilotto S, Osman G, Cappuzzo F, Cecere F, Riccardi F, Scotti V, Martelli O, Borra G, Maiello E, Rossi A, Graziano P, Gregorc V, Casartelli C, Sergi C, Del Conte A, Delmonte A, Bareggi C, Cortinovis D, Rizzo P, Tabbò F, Rossi G, Bria E, Galetta D, Tiseo M, Di Maio M, Novello S.

Clin Transl Oncol. 2019 Oct 19. doi: 10.1007/s12094-019-02222-8. [Epub ahead of print]

PMID:
31630357
3.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
4.

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around.

Gkountakos A, Sartori G, Falcone I, Piro G, Ciuffreda L, Carbone C, Tortora G, Scarpa A, Bria E, Milella M, Rosell R, Corbo V, Pilotto S.

Cancers (Basel). 2019 Aug 9;11(8). pii: E1141. doi: 10.3390/cancers11081141. Review.

5.

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.

Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M.

Clin Transl Oncol. 2019 Aug 7. doi: 10.1007/s12094-019-02193-w. [Epub ahead of print]

PMID:
31392645
6.

Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors.

Iezzi R, Larici AR, Posa A, Carchesio F, Congedo MT, Tagliaferri L, Cassano A, D'argento E, Mantini G, Rodolfino E, Margaritora S, Bria E, Tortora G, Valentini V, Manfredi R.

Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6554-6561. doi: 10.26355/eurrev_201908_18541.

7.

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

Rossi E, Schinzari G, Zizzari IG, Maiorano BA, Pagliara MM, Sammarco MG, Fiorentino V, Petrone G, Cassano A, Rindi G, Bria E, Blasi MA, Nuti M, Tortora G.

Cancers (Basel). 2019 Jul 26;11(8). pii: E1055. doi: 10.3390/cancers11081055. Review.

8.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32583. [Epub ahead of print]

PMID:
31330065
9.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.

PMID:
31319983
10.

Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.

Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer).

Lung Cancer. 2019 Aug;134:121-126. doi: 10.1016/j.lungcan.2019.06.011. Epub 2019 Jun 11.

PMID:
31319970
11.

PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer.

Iacovelli R, Ciccarese C, Brunelli M, Bogina G, Munari E, Bimbatti D, Mosillo C, Fantinel E, Bria E, Martignoni G, Tortora G.

J Immunother. 2019 Sep;42(7):269-273. doi: 10.1097/CJI.0000000000000287.

PMID:
31261165
12.

Exploring the molecular and biological background of lung neuroendocrine tumours.

Simbolo M, Di Noia V, D'Argento E, Milella M, Scarpa A, Tortora G, Bria E, Pilotto S.

J Thorac Dis. 2019 May;11(Suppl 9):S1194-S1198. doi: 10.21037/jtd.2019.03.66. No abstract available.

13.

Muscle derangement and alteration of the nutritional machinery in NSCLC.

Trestini I, Gkountakos A, Carbognin L, Avancini A, Lanza M, Molfino A, Friso S, Corbo V, Tortora G, Scarpa A, Milella M, Bria E, Pilotto S.

Crit Rev Oncol Hematol. 2019 Sep;141:43-53. doi: 10.1016/j.critrevonc.2019.06.007. Epub 2019 Jun 15. Review.

PMID:
31228648
14.

[Use of the Lean methodology in the management of cancer patients in a University Hospital, Italy: First results].

De Belvis AG, Angioletti C, Traglia S, Ghirardini G, Barbara A, Giubbini G, Specchia ML, Cambieri A, Boccia S, Bria E, Valentini V.

Ig Sanita Pubbl. 2019 Jan-Feb;75(1):62-76. Italian.

PMID:
31185491
15.

Pembrolizumab as first-line treatment for metastatic uveal melanoma.

Rossi E, Pagliara MM, Orteschi D, Dosa T, Sammarco MG, Caputo CG, Petrone G, Rindi G, Zollino M, Blasi MA, Cassano A, Bria E, Tortora G, Schinzari G.

Cancer Immunol Immunother. 2019 Jul;68(7):1179-1185. doi: 10.1007/s00262-019-02352-6. Epub 2019 Jun 7.

16.

PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis.

Rossi A, Noia VD, Gkountakos A, D'Argento E, Sartori G, Vita E, Monteverdi S, Lombardo F, Iacovelli R, Carbognin L, Sperduti I, Milella M, Tortora G, Bria E, Pilotto S.

Immunotherapy. 2019 Jul;11(10):921-930. doi: 10.2217/imt-2018-0198. Epub 2019 Jun 3.

PMID:
31155995
17.

Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.

Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, Gori S, Giarratano T, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P; Veneto Oncology Network.

Oncologist. 2019 May 31. pii: theoncologist.2019-0103. doi: 10.1634/theoncologist.2019-0103. [Epub ahead of print]

PMID:
31152079
18.

Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report.

Bertelli G, Trovato R, Ugel S, Bria E, Milella M, Bronte V, Pilotto S.

Clin Lung Cancer. 2019 Jul;20(4):e514-e516. doi: 10.1016/j.cllc.2019.04.013. Epub 2019 Apr 28. No abstract available.

PMID:
31122866
19.

Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions.

Iacovelli R, Ciccarese C, Schinzari G, Maiorano BA, Rossi E, Pierconti F, Bassi PF, Bria E, Tortora G.

Crit Rev Oncol Hematol. 2019 Jul;139:83-86. doi: 10.1016/j.critrevonc.2019.05.005. Epub 2019 May 11. Review.

PMID:
31112886
20.

Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.

Simbolo M, Barbi S, Fassan M, Mafficini A, Ali G, Vicentini C, Sperandio N, Corbo V, Rusev B, Mastracci L, Grillo F, Pilotto S, Pelosi G, Pelliccioni S, Lawlor RT, Tortora G, Fontanini G, Volante M, Scarpa A, Bria E.

J Thorac Oncol. 2019 Sep;14(9):1651-1661. doi: 10.1016/j.jtho.2019.05.003. Epub 2019 May 11.

21.

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma.

Rossi E, Maiorano BA, Pagliara MM, Sammarco MG, Dosa T, Martini M, Rindi G, Bria E, Blasi MA, Tortora G, Schinzari G.

Front Oncol. 2019 Apr 5;9:232. doi: 10.3389/fonc.2019.00232. eCollection 2019.

22.

Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"

Di Noia V, Vita E, Ferrara M, Strippoli A, Basso M, Schinzari G, Cassano A, Bria E, Barone C, D'Argento E.

Curr Treat Options Oncol. 2019 Feb 21;20(3):23. doi: 10.1007/s11864-019-0616-7. Review.

PMID:
30790063
23.

Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine.

Di Noia V, D'Argento E, Pilotto S, Ferrara MG, Milella M, Tortora G, Bria E.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S312-S317. doi: 10.21037/tlcr.2018.12.08. No abstract available.

24.

Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis.

Ciccarese C, Iacovelli R, Bria E, Mosillo C, Bimbatti D, Fantinel E, Bisogno I, Brunelli M, Tortora G.

Semin Oncol. 2019 Feb;46(1):65-72. doi: 10.1053/j.seminoncol.2019.01.001. Epub 2019 Jan 14.

PMID:
30665685
25.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J.

Ann Oncol. 2019 Jul 1;30(7):1180. doi: 10.1093/annonc/mdy536. No abstract available.

PMID:
30624609
26.

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P.

Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7.

27.

Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?

Pilotto S, Carbognin L, Rossi A, Tortora G, Bria E.

Semin Oncol. 2018 Jun;45(3):176-180. doi: 10.1053/j.seminoncol.2018.08.002. Epub 2018 Sep 22.

PMID:
30262399
28.

Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis†.

Chiappetta M, Leuzzi G, Sperduti I, Bria E, Mucilli F, Lococo F, Spaggiari L, Ratto GB, Filosso PL, Facciolo F.

Eur J Cardiothorac Surg. 2019 Mar 1;55(3):405-412. doi: 10.1093/ejcts/ezy311.

PMID:
30202953
29.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.

30.

Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer.

Iacovelli R, Ciccarese C, Mosillo C, Bimbatti D, Fantinel E, Stefani L, Simbolo M, Romano M, Mazzarotto R, Brunelli M, Bria E, Scarpa A, Lawlor RT, Artibani W, Tortora G.

Target Oncol. 2018 Oct;13(5):649-655. doi: 10.1007/s11523-018-0588-8.

PMID:
30167971
31.

Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.

Moro M, Caiola E, Ganzinelli M, Zulato E, Rulli E, Marabese M, Centonze G, Busico A, Pastorino U, de Braud FG, Vernieri C, Simbolo M, Bria E, Scarpa A, Indraccolo S, Broggini M, Sozzi G, Garassino MC.

J Thorac Oncol. 2018 Nov;13(11):1692-1704. doi: 10.1016/j.jtho.2018.07.102. Epub 2018 Aug 24.

32.

Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis.

Iacovelli R, Ciccarese C, Bria E, Bimbatti D, Fantinel E, Mosillo C, Bisogno I, Brunelli M, Tortora G, Porta C.

Cancer Treat Rev. 2018 Nov;70:112-117. doi: 10.1016/j.ctrv.2018.08.007. Epub 2018 Aug 20. Review.

PMID:
30145397
33.

Role of mTOR Signaling in Tumor Microenvironment: An Overview.

Conciatori F, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M, Ciuffreda L.

Int J Mol Sci. 2018 Aug 19;19(8). pii: E2453. doi: 10.3390/ijms19082453. Review.

34.

Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer.

Trestini I, Carbognin L, Monteverdi S, Zanelli S, De Toma A, Bonaiuto C, Nortilli R, Fiorio E, Pilotto S, Di Maio M, Gasbarrini A, Scambia G, Tortora G, Bria E.

Crit Rev Oncol Hematol. 2018 Sep;129:54-66. doi: 10.1016/j.critrevonc.2018.06.011. Epub 2018 Jun 21. Review.

PMID:
30097238
35.

Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.

di Noia V, D'Argento E, Pilotto S, Grizzi G, Caccese M, Iacovelli R, Tortora G, Bria E.

Expert Opin Biol Ther. 2018 Sep;18(9):937-945. doi: 10.1080/14712598.2018.1508445. Epub 2018 Aug 9. Review.

PMID:
30075697
36.

Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.

Gkountakos A, Pilotto S, Mafficini A, Vicentini C, Simbolo M, Milella M, Tortora G, Scarpa A, Bria E, Corbo V.

Carcinogenesis. 2018 Jun 28. doi: 10.1093/carcin/bgy086. [Epub ahead of print]

PMID:
29955840
37.

Do immune checkpoint inhibitors need new studies methodology?

Ferrara R, Pilotto S, Caccese M, Grizzi G, Sperduti I, Giannarelli D, Milella M, Besse B, Tortora G, Bria E.

J Thorac Dis. 2018 May;10(Suppl 13):S1564-S1580. doi: 10.21037/jtd.2018.01.131. Review.

38.

Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.

Simbolo M, Vicentini C, Ruzzenente A, Brunelli M, Conci S, Fassan M, Mafficini A, Rusev B, Corbo V, Capelli P, Bria E, Pedron S, Turri G, Lawlor RT, Tortora G, Bassi C, Guglielmi A, Scarpa A.

Sci Rep. 2018 May 8;8(1):7119. doi: 10.1038/s41598-018-25669-1.

39.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J.

Ann Oncol. 2018 Oct 1;29(10):2151. doi: 10.1093/annonc/mdx803. No abstract available.

PMID:
29701763
40.

Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy.

Trestini I, Carbognin L, Sperduti I, Bonaiuto C, Auriemma A, Melisi D, Salvatore L, Bria E, Tortora G.

Eur J Clin Nutr. 2018 May;72(5):772-779. doi: 10.1038/s41430-018-0155-5. Epub 2018 Mar 26.

PMID:
29581564
41.

Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis.

Di Maio M, Baratelli C, Bironzo P, Vignani F, Bria E, Sperti E, Marcato M, Roila F.

Crit Rev Oncol Hematol. 2018 Apr;124:21-28. doi: 10.1016/j.critrevonc.2018.02.001. Epub 2018 Feb 7. Review.

PMID:
29548482
42.

The obesity paradox in cancer: clinical insights and perspectives.

Trestini I, Carbognin L, Bonaiuto C, Tortora G, Bria E.

Eat Weight Disord. 2018 Apr;23(2):185-193. doi: 10.1007/s40519-018-0489-y. Epub 2018 Feb 28. Review.

PMID:
29492860
43.

Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.

Pelosi G, Bianchi F, Dama E, Simbolo M, Mafficini A, Sonzogni A, Pilotto S, Harari S, Papotti M, Volante M, Fontanini G, Mastracci L, Albini A, Bria E, Calabrese F, Scarpa A.

Virchows Arch. 2018 Apr;472(4):567-577. doi: 10.1007/s00428-018-2307-3. Epub 2018 Feb 1.

44.

mTOR Cross-Talk in Cancer and Potential for Combination Therapy.

Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M.

Cancers (Basel). 2018 Jan 19;10(1). pii: E23. doi: 10.3390/cancers10010023. Review.

45.

The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.

Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, Muraglia A, Porcaro AB, Siracusano S, Brunelli M, Mazzarotto R, Artibani W, Tortora G.

Clin Genitourin Cancer. 2018 Jun;16(3):e645-e653. doi: 10.1016/j.clgc.2017.12.007. Epub 2017 Dec 27.

PMID:
29339044
46.

Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey.

Carnio S, Galetta D, Scotti V, Cortinovis DL, Antonuzzo A, Pisconti S, Rossi A, Martelli O, Cecere FL, Lunghi A, Del Conte A, Montagna ES, Topulli J, Pelizzoni D, Rapetti SG, Gianetta M, Pacchiana MV, Pegoraro V, Cataldo N, Bria E, Novello S.

Support Care Cancer. 2018 Jun;26(6):1841-1849. doi: 10.1007/s00520-017-4004-1. Epub 2017 Dec 21.

PMID:
29270827
47.

Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment.

Pilotto S, Sperduti I, Leuzzi G, Chiappetta M, Mucilli F, Ratto GB, Lococo F, Filosso PL, Spaggiari L, Novello S, Milella M, Santo A, Scarpa A, Infante M, Tortora G, Facciolo F, Bria E.

J Thorac Oncol. 2018 Apr;13(4):568-575. doi: 10.1016/j.jtho.2017.12.003. Epub 2017 Dec 18.

48.

The development of PARP as a successful target for cancer therapy.

Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, Melisi D.

Expert Rev Anticancer Ther. 2018 Feb;18(2):161-175. doi: 10.1080/14737140.2018.1419870. Epub 2017 Dec 26. Review.

PMID:
29260919
49.

Biosimilars as a strategy to improve sustainability.

Bria E, Conte P.

ESMO Open. 2017 May 29;2(2):e000192. doi: 10.1136/esmoopen-2017-000192. eCollection 2017. No abstract available.

50.

Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer.

Benato C, Pilotto S, Infante M, Bria E.

J Thorac Dis. 2017 Sep;9(9):2743-2745. doi: 10.21037/jtd.2017.07.118. No abstract available.

Supplemental Content

Support Center